CLINICAL TRIAL: ANTIRETROVIRAL ACTIVITY OF RALTEGRAVIR IN HIV-1 INFECTED CHILDRE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 主要目的： 1.评价在HIV-1初始稳定背景治疗中添加雷特格韦的短期安全性和耐受性 2.评价在稳定背景治疗中加入雷格韦的稳态血药浓度曲线和药代动力学参数 3.评价选择剂量的雷特格韦联合优化背景治疗的安全性和耐受性

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives: 1. to evaluate the short term safety tolerability of raltegravir added to an initial stable background therapy in HIV-1 2. to evaluate the steady state plasma concentration profiles and pharmacokinetic parameters of raltgravir added to the stable background therapy 3. to evaluate the safety and tolerability of raltegravir at the selkected dose in combination with optimized background therapy